Ameriprise
RIGL icon

Ameriprise’s Rigel Pharmaceuticals RIGL Stock Holding History

Ameriprise’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-37,250
Closed -$1.11M – 3976
2022
Q1 		$1.11M Buy
37,250
+10,970
+42% +$297K ﹤0.01% 3166
2021
Q4 		$696K Buy
+26,280
New +$793K ﹤0.01% 3408
2020
Q1 		– Sell
-7,383
Closed -$158K – 3721
2019
Q4 		$158K Buy
+7,383
New +$152K ﹤0.01% 3610
2014
Q4 		– Sell
-11
Closed – – 4258
2014
Q3 		$0 Sell
11
-3
-21% -$85 ﹤0.01% 5878
2014
Q2 		$1K Buy
+14
New +$476 ﹤0.01% 5370
2013
Q4 		– Sell
-543
Closed -$19K – 5384
2013
Q3 		$19K Hold
543
– – ﹤0.01% 4454
2013
Q2 		$18K Buy
+543
New +$24.6K ﹤0.01% 4361

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise's RIGL Position: Q2 2022 in Review

Ameriprise sold out of Rigel Pharmaceuticals (RIGL) in Q2 2022, closing a stake of 37,250 shares — an estimated $1.11M sold.

Ameriprise first reported a position in RIGL in Q2 2013 and held it in 7 quarters. The position peaked at $1.11M in Q1 2022. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2022.

  • Ameriprise reported no remaining Rigel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Ameriprise sold 37,250 Rigel Pharmaceuticals shares in Q2 2022, an estimated $1.11M.
  • Ameriprise first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 7 quarters.
  • Ameriprise's Rigel Pharmaceuticals position peaked at $1.11M in Q1 2022.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2022.

Based on Ameriprise's 13F filing for Q2 2022, filed 15 Aug 2022.